New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ceftriaxone sodium 2.158 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd) - powder for infusion - 2 g - active: ceftriaxone sodium 2.158 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd) - infections caused by pathogens sensitive to ceftriaxone e.g.: - sepsis; - meningitis; - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms; - renal and urinary tract infections; - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; - genital infections, including gonorrhoea. - perioperative prophylaxis of infections.

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - ceftriaxone sodium - powder for solution for injection/infusion - 2 gram(s) - third-generation cephalosporins; ceftriaxone

Canada - English - Health Canada

fresenius kabi canada ltd - ceftriaxone (ceftriaxone sodium) - powder for solution - 100g - ceftriaxone (ceftriaxone sodium) 100g - third generation cephalosporins

Ireland - English - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - ceftriaxone sodium - powder for solution for injection/infusion - 2 gram(s) - third-generation cephalosporins; ceftriaxone

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ceftriaxone sodium 1.193 g (present as 1.193g ceftriaxone na*3.5h2o. eq 1.0793g of ceftriaxone na anhyd or 1g ceftriaxone anhyd);  ;   - powder for injection - 1 g - active: ceftriaxone sodium 1.193 g (present as 1.193g ceftriaxone na*3.5h2o. eq 1.0793g of ceftriaxone na anhyd or 1g ceftriaxone anhyd)    

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ceftriaxone sodium 2.386 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd);  ;   - powder for injection - 2 g - active: ceftriaxone sodium 2.386 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd)    

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

harbin pharmaceutical group co. - ceftriaxone (ceftriaxone sodium) - powder for solution for injection - 1000mg

United States - English - NLM (National Library of Medicine)

civica, inc. - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - before instituting treatment with ceftriaxone for injection, usp, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: lower respiratory tract infections caused by streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, escherichia coli, enterobacter aerogenes, proteus mirabilis or serratia marcescens. acute bacterial otitis media caused by streptococcus pneumoniae, haemophilus influenzae (including beta‑lactamase producing strains) or moraxella catarrhalis (including beta-lactamase producing strains). note: in one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection, usp compared to 10 days of oral therapy. in a second study comparable cure rates were observed between single dose of ceftriaxone for injection, usp and the comparator. the potentially lower clinical cure rate of ceftriaxone for injection, usp should be balanced against the potential advantages of parenteral therapy (see clinical studies ). skin and skin structure infections caused by staphylococcus aureus, staphylococcus epidermidis, streptococcus pyogenes , viridans group streptococci, escherichia coli, enterobacter cloacae, klebsiella oxytoca, klebsiella pneumoniae, proteus mirabilis, morganella morganii1 , pseudomonas aeruginosa, serratia marcescens, acinetobacter calcoaceticus, bacteroides fragilis1 or peptostreptococcus species. urinary tract infections (complicated and uncomplicated) caused by escherichia coli, proteus mirabilis, proteus vulgaris, morganella morganii or klebsiella pneumoniae. uncomplicated gonorrhea (cervical/urethral and rectal) caused by neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase‑producing strains of neisseria gonorrhoeae. pelvic inflammatory disease caused by neisseria gonorrhoeae. ceftriaxone for injection, usp, like other cephalosporins, has no activity against chlamydia trachomatis . therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. bacterial septicemia caused by staphylococcus aureus, streptococcus pneumoniae, escherichia coli, haemophilus influenzae or klebsiella pneumoniae. bone and joint infections caused by staphylococcus aureus, streptococcus pneumoniae, escherichia coli, proteus mirabilis, klebsiella pneumoniae or enterobacter species. intra-abdominal infections caused by escherichia coli, klebsiella pneumoniae, bacteroides fragilis, clostridium species (note: most strains of clostridium difficile are resistant) or peptostreptococcus species. meningitis caused by haemophilus influenzae, neisseria meningitidis or streptococcus pneumoniae. ceftriaxone for injection, usp has also been used successfully in a limited number of cases of meningitis and shunt infection caused by staphylococcus epidermidis1 and escherichia coli.1 1 efficacy for this organism in this organ system was studied in fewer than ten infections. the preoperative administration of a single 1 gm dose of ceftriaxone for injection, usp may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). although ceftriaxone for injection, usp has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. when administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone for injection, usp provides protection from most infections due to susceptible organisms throughout the course of the procedure. ceftriaxone is contraindicated in patients with known hypersensitivity to ceftriaxone, any of its excipients or to any other cephalosporin. patients with previous hypersensitivity reactions to penicillin and other beta lactam antibacterial agents may be at greater risk of hypersensitivity to ceftriaxone (see warnings – hypersensitivity ). premature neonates: ceftriaxone is contraindicated in premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age). hyperbilirubinemic neonates: hyperbilirubinemic neonates should not be treated with ceftriaxone. ceftriaxone can displace bilirubin from its binding to serum albumin, leading to a risk of bilirubin encephalopathy in these patients. ceftriaxone is contraindicated in neonates (≤ 28 days) if they require (or are expected to require) treatment with calcium‑containing iv solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone‑calcium (see clinical pharmacology , warnings and dosage and administration ). cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving ceftriaxone and calcium-containing fluids. in some of these cases, the same intravenous infusion line was used for both ceftriaxone and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. there have been no similar reports in patients other than neonates. intravenous administration of ceftriaxone solutions containing lidocaine is contraindicated. when lidocaine solution is used as a solvent with ceftriaxone for intramuscular injection, exclude all contraindications to lidocaine. refer to the prescribing information of lidocaine.

Ireland - English - HPRA (Health Products Regulatory Authority)

as kalceks - ceftriaxone sodium - powder for solution for injection/infusion - third-generation cephalosporins; ceftriaxone

Ireland - English - HPRA (Health Products Regulatory Authority)

as kalceks - ceftriaxone sodium - powder for solution for injection/infusion - third-generation cephalosporins; ceftriaxone